A5091773013- Mesenchymal stem cell research
- Wound Healing and Treatments
- Cancer Cells and Metastasis
- Immunotherapy and Immune Responses
- Ocular Surface and Contact Lens
- Diabetic Foot Ulcer Assessment and Management
- Corneal Surgery and Treatments
- Tissue Engineering and Regenerative Medicine
- Renal and related cancers
- RNA Interference and Gene Delivery
- Corneal surgery and disorders
- CAR-T cell therapy research
- Pressure Ulcer Prevention and Management
- Diagnosis and Treatment of Venous Diseases
- Hair Growth and Disorders
- Hedgehog Signaling Pathway Studies
- Phagocytosis and Immune Regulation
- Cellular Mechanics and Interactions
- Skin and Cellular Biology Research
- Genetic and Kidney Cyst Diseases
Rheacell (Germany)
2022-2024
Brigham and Women's Hospital
2020
Abstract Background While rapid healing of diabetic foot ulcers (DFUs) is highly desirable to avoid infections, amputations and life-threatening complications, DFUs often respond poorly standard treatment. GMP-manufactured skin-derived ABCB5 + mesenchymal stem cells (MSCs) might provide a new adjunctive DFU treatment, based on their remarkable skin wound homing engraftment potential, ability adaptively inflammatory signals, healing-promoting efficacy in mouse models human chronic venous...
BACKGROUNDRecessive dystrophic epidermolysis bullosa (RDEB) is a rare, devastating, and life-threatening inherited skin fragility disorder that comes about due to lack of functional type VII collagen, for which no effective therapy exists. ABCB5+ dermal mesenchymal stem cells (ABCB5+ MSCs) possess immunomodulatory, inflammation-dampening, tissue-healing capacities. In Col7a1-/- mouse model RDEB, treatment with MSCs markedly extended the animals' lifespans.METHODSIn this international,...
Mesenchymal stromal cells (MSCs) hold promise for the treatment of tissue damage and injury. However, MSCs comprise multiple subpopulations with diverse properties, which could explain inconsistent therapeutic outcomes seen among attempts. Recently, adenosine triphosphate-binding cassette transporter ABCB5 has been shown to identify a novel dermal immunomodulatory MSC subpopulation. The authors have established validated Good Manufacturing Practice (GMP)-compliant expansion manufacturing...
A significant number of chronic venous ulcers (CVUs) fail to heal despite guideline-conform standard care. Skin-derived ABCB5+ mesenchymal stem cells (MSCs) can dampen the sustained IL-1β-driven inflammation present in wounds. Based on their wound healing-facilitating effects a mouse CVU model and an autologous first-in-human study, MSCs have emerged as potential candidate for cell-based advanced therapy non-healing CVUs. In interventional, multicenter, single-arm, phase I/IIa clinical...
While therapeutic success of the limbal tissue or cell transplantation to treat severe cases stem (LSC) deficiency (LSCD) strongly depends on percentage LSCs within transplanted cells, prospective LSC enrichment has been hampered by intranuclear localization previously reported marker p63. The recent identification ATP-binding cassette transporter ABCB5 as a plasma membrane-spanning that are capable restoring cornea and development an antibody directed against extracellular loop molecule...
Human dermal mesenchymal stromal cells (MSCs) expressing the ATP-binding cassette (ABC) efflux transporter ABCB5 represent an easily accessible MSC population that, based on preclinical and first-in-human data, holds significant promise to treat a broad spectrum of conditions associated not only with skin-related but also systemic inflammatory and/or degenerative processes.We have developed validated Good Manufacturing Practice-compliant expansion manufacturing process by which ABCB5+ MSCs...
BackgroundGiven the high level of product complexity and limited regulatory guidance, designing implementing appropriate potency assays is often most challenging part establishing a quality control testing matrix for cell-based medicinal product. Among elusive tasks are selection suitable read-out parameters, development assay designs that closely model pathophysiological conditions, validation methods. Here we describe these challenges how they were addressed in developing an measures...
Cystic kidney disease (CKD) is a heterogeneous group of genetic disorders and one the most common causes end-stage renal disease. Here, we investigate potential effects long-term human stem cell treatment on function gene expression profile PKD/Mhm (Cy/+) rats. Human adipose-derived stromal cells (ASC) skin-derived ABCB5+ (2 × 106) were infused intravenously or intraperitoneally monthly, over 6 months. Additionally, ASC ABCB5+-derived conditioned media administrated intraperitoneally. The...
Abstract Background While rapid healing of diabetic foot ulcers (DFUs) is highly desirable to avoid infections, amputations and life-threatening complications, DFUs often respond poorly standard treatment. GMP-manufactured skin-derived ABCB5 + mesenchymal stem cells (MSCs) might provide a new adjunctive DFU treatment, based on their remarkable skin wound homing engraftment potential, ability adaptively inflammatory signals, healing-promoting efficacy in mouse models human chronic venous...
Abstract Background: Human dermal mesenchymal stromal cells (MSCs) expressing the ATP-binding cassette (ABC) efflux transporter ABCB5 represent an easily accessible MSC population that, based on preclinical and first-in-human data, holds significant promise to treat a broad spectrum of conditions associated not only with skin-related but also systemic inflammatory and/or degenerative processes. Methods: We have developed validated Good Manufacturing Practice-compliant expansion manufacturing...
Abstract Background: While therapeutic success of limbal tissue or cell transplantation to treat severe cases stem (LSC) deficiency (LSCD) strongly depends on the percentage LSCs within transplanted cells, prospective LSC enrichment has been hampered by intranuclear localization previously reported marker p63. The recent identification ATP-binding cassette transporter ABCB5 as a plasma membrane-spanning that are capable restoring cornea and development an antibody directed against...
Abstract Background: Human dermal mesenchymal stromal cells (MSCs) expressing the ATP-binding cassette (ABC) efflux transporter ABCB5 represent an easily accessible MSC population that, based on preclinical and first-in-human data, holds significant promise to treat a broad spectrum of conditions associated not only with skin-related but also systemic inflammatory and/or degenerative processes. Methods: We developed validated Good Manufacturing Practice-compliant expansion manufacturing...